Pancytopenia Causes and Management

Etiological Categories

Pancytopenia is most commonly caused by bone marrow disorders, including megaloblastic anemia, aplastic anemia, myelodysplastic syndromes, and hematological malignancies, followed by peripheral destruction or sequestration mechanisms, with infections being a leading cause in some populations 1
Myelodysplastic syndromes are characterized by ineffective hematopoiesis and dysplastic changes, affecting 10.7% of cases 2
Hemophagocytic syndrome can present with pancytopenia and requires prompt immunosuppressive treatment 3
Radiation exposure can cause acute radiation syndrome with hematopoietic failure 4

Diagnostic Approach

Complete blood count with differential is essential to confirm pancytopenia and assess severity 5
Peripheral blood smear examination is critical to exclude pseudothrombocytopenia and identify morphological abnormalities like schistocytes or blasts 1, 5
Reticulocyte count helps differentiate between production defects and peripheral destruction 1
Bone marrow examination is indicated in most cases of pancytopenia, especially in patients over 60 years of age, those with systemic symptoms or abnormal physical findings, and cases where diagnosis remains unclear after initial testing 1, 6
HIV and HCV testing is recommended in all adult patients with pancytopenia 1, 5
Autoimmune workup, including ANA and anti-dsDNA, should be considered if systemic symptoms suggest autoimmune disease 3

Management Approach

Treat the underlying cause is the primary focus of management, with supportive care, including transfusions for symptomatic anemia or severe thrombocytopenia 7
Immunosuppressive therapy is recommended for non-severe aplastic anemia cases 4
Hematopoietic stem cell transplantation is considered for severe aplastic anemia cases in appropriate candidates 7
Hypomethylating agents, such as azacitidine, are recommended for higher-risk myelodysplastic syndromes patients not eligible for stem cell transplantation 2, 8
Corticosteroids are first-line therapy for immune thrombocytopenia component 5
Antimicrobial therapy should be directed at the specific pathogen in infection-related pancytopenia, with eradication therapy for H. pylori if positive, and antiviral therapy for HIV/HCV 1, 5, 7

Pancytopenia Causes and Considerations

Etiological Categories and Diagnostic Approaches

Chemotherapy agents cause pancytopenia through direct bone marrow suppression and mucosal barrier disruption, as noted by the National Comprehensive Cancer Network 9
Immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-L1 agents) cause immune-related hematological toxicity in less than 5% of patients, but with significant mortality risk, according to the European Society for Medical Oncology 10
In immunotherapy-treated patients, the European Society for Medical Oncology recommends maintaining a low threshold for bone marrow examination to rule out marrow infiltration, secondary MDS, or aplastic anemia 10
SAMD9/SAMD9L-Associated Syndromes account for 8-18% of childhood MDS cases, presenting with cytopenias, immunodeficiency, and risk for childhood-onset bone marrow failure, as reported by the American Association for Cancer Research 11
In patients with active infection and pancytopenia, the European Hematology Association suggests considering less myelosuppressive regimens rather than purine analogs to avoid prolonged granulocytopenia 12

Pancytopenia Causes and Diagnostic Considerations

Infectious Causes

Brucellosis commonly presents with mild transaminitis and pancytopenia, with bone marrow culture having the highest diagnostic sensitivity 13

Drug-Induced Causes

Methotrexate can rarely cause pancytopenia even with low-dose weekly therapy or after single doses, particularly in patients with impaired renal function, medication errors, or concomitant sulfonamide-based medications 14
Methotrexate-induced pancytopenia may occur 4-6 weeks after dose increases 14

Cytogenetic Analysis in Pancytopenia

Diagnostic Testing

Cytogenetic analysis of bone marrow is essential for diagnosing myelodysplastic syndromes and identifying specific chromosomal abnormalities that guide prognosis and treatment, as recommended by the National Comprehensive Cancer Network 15, 16
Copper and ceruloplasmin levels may be indicated in select cases, particularly with history of gastrointestinal surgery, vitamin B12 deficiency, or vacuolation of myeloid/erythroid precursors on bone marrow examination, according to the National Comprehensive Cancer Network 16

Specific Clinical Contexts

In cases with accompanying eosinophilia, optical genome mapping or FISH may be superior to conventional cytogenetics for detecting entity-defining abnormalities such as BCR::ABL1, PDGFRA, PDGFRB, FGFR1, and JAK2 rearrangements, as suggested by the American Journal of Hematology 15

Pancytopenia Causes and Diagnostic Considerations

Infectious and Autoimmune Causes

Hemophagocytic lymphohistiocytosis (HLH) presents with pancytopenia, fever, hepatosplenomegaly, hypertriglyceridemia, hypofibrinogenemia, and elevated ferritin, as reported by the American Academy of Allergy, Asthma, and Immunology 17
Ehrlichiosis (E. chaffeensis) causes pancytopenia with leukopenia and thrombocytopenia, according to the Centers for Disease Control and Prevention (CDC) 18
Chediak-Higashi syndrome presents with partial oculocutaneous albinism, bacterial infections, and pancytopenia during the accelerated phase (HLH), as noted by the American Academy of Allergy, Asthma, and Immunology 17
Griscelli syndrome type 2 manifests with pigmentary dilution, neurological abnormalities, pyogenic infections, and potential HLH development, as reported by the American Academy of Allergy, Asthma, and Immunology 17

High-Risk Populations and Diagnostic Patterns

Children under 10 years have the highest case-fatality rate despite frequently having milder infections, according to the CDC 18
Immunosuppressed patients (HIV, organ transplant, splenectomy) experience more severe symptoms and higher mortality, as reported by the CDC 18
Patients receiving sulfonamide antimicrobials may be predisposed to severe ehrlichial illness, according to the CDC 18

Diagnostic Considerations

In patients treated with immunotherapy, persistent post-treatment cytopenias or progressive cytopenias should be evaluated for autoimmune causes with peripheral smear, reticulocyte count, and assessment for hemolysis, as recommended by the Journal for ImmunoTherapy of Cancer 19
Complete blood count should be monitored at treatment initiation, at intervals during therapy, and periodically in long-term survivors to detect immune-related adverse events, according to the Journal for ImmunoTherapy of Cancer 19
In immunotherapy-treated patients, maintain a low threshold for bone marrow examination to rule out marrow infiltration, secondary myelodysplastic syndromes, or aplastic anemia, with a high clinical suspicion for hematologic immune-related adverse events, as noted in the Journal for ImmunoTherapy of Cancer 19

Pancytopenia Diagnosis and Management

Etiological Categories

The American College of Physicians recommends that hematological malignancies, including acute and chronic leukemias, be considered as a cause of pancytopenia, as they can directly suppress normal hematopoiesis through bone marrow infiltration 20
Chemotherapy agents, such as purine analog-based therapies and alemtuzumab, can cause pancytopenia through direct bone marrow suppression, with monitoring for myelosuppression essential during treatment 20
The American Thoracic Society suggests that hypersplenism with sequestration is a common cause of hematologic abnormalities in sarcoidosis, often more frequent than bone marrow involvement 21

Diagnostic Evaluation

The National Comprehensive Cancer Network recommends that vitamin B12, folate, and iron studies be obtained prior to treatment, as megaloblastic anemia is a common reversible cause of pancytopenia 22
The American College of Physicians recommends that HIV and HCV testing be performed in all adult patients with pancytopenia, as these infections can cause cytopenias 20

Management Priorities

The National Comprehensive Cancer Network suggests that appropriate supportive care, including transfusions for symptomatic anemia or severe thrombocytopenia, is essential to ensure full-dose chemotherapy is delivered on schedule in adjuvant and neoadjuvant settings 23
The American Society of Clinical Oncology recommends that evaluating the need for erythropoietin support in patients whose hemoglobin levels are less than 11 g/dL may be particularly important, especially in lung cancer patients 24

Viral Causes of Pancytopenia

Clinical Presentation and Diagnosis

The American College of Critical Care Medicine suggests that citomegalovirus (CMV) can cause post-transfusion mononucleosis syndrome with high fever, pancytopenia, and atypical lymphocytosis, typically starting one month after transfusion 25
Fiebre persistente a pesar de antibióticos de amplio espectro suggests viral etiology, especially if bacterial cultures are negative, according to the American College of Critical Care Medicine 25
Exantema maculopapular or vesicular may indicate rickettsial or measles virus infections, as reported in the Journal of Infection 26
Ganciclovir or valganciclovir is recommended for CMV in immunocompromised patients with severe disease, as suggested by the American College of Critical Care Medicine 25

Treatment and Management

The American College of Critical Care Medicine recommends ganciclovir or valganciclovir for CMV in immunocompromised patients with severe disease 25

Diagnostic and Management Approach to Pancytopenia

Initial Diagnostic Workup

Measure lactate dehydrogenase (LDH) and uric acid to assess for hemolysis and tumor lysis risk in patients with pancytopenia 27

Bone Marrow Examination

When immunotherapy-related pancytopenia is suspected, maintain a low threshold to rule out marrow infiltration, secondary myelodysplastic syndrome, or aplastic anemia, as recommended by the Annals of Oncology 28

Immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-L1) cause immune-related hematological toxicity in less than 5% of patients but with significant mortality risk, according to the Annals of Oncology 28

Monitor CBC at treatment initiation, at intervals during therapy, and periodically in long-term survivors, as recommended by the Journal for ImmunoTherapy of Cancer 29
Evaluate persistent or progressive cytopenias with peripheral smear, reticulocyte count, and assessment for hemolysis, following guidelines from the Journal for ImmunoTherapy of Cancer 29
Early hematology consultation is mandatory, and immunotherapy should be discontinued while investigating significant hematological toxicity, as advised by the Annals of Oncology 28

Common Pitfalls to Avoid

In immunotherapy patients, 40% of immune-related autoimmune hemolytic anemia cases are direct antiglobulin test (Coombs) negative, requiring alternative diagnostic approaches, according to the Annals of Oncology 28
Do not delay hematology consultation for unexplained cytopenias or when bone marrow examination is indicated, as recommended by the Journal for ImmunoTherapy of Cancer 29

Evidence‑Based Recommendations for the Evaluation and Management of Pancytopenia

Laboratory Assessment for Hemolysis

Measure lactate dehydrogenase, bilirubin, and haptoglobin to assess for hemolysis and ineffective hematopoiesis in patients with pancytopenia. 30

Peripheral‑Smear Findings Requiring Immediate Action

Detection of blasts on the peripheral blood smear mandates urgent hematology consultation and bone‑marrow examination to diagnose acute leukemia. 30

Indications for Bone‑Marrow Examination (Aspirate, Biopsy, and Cytogenetics)

Perform bone‑marrow aspiration and biopsy with cytogenetic analysis in any of the following situations:
30

Role of Cytogenetic Analysis

Routine cytogenetic analysis of bone‑marrow specimens is mandatory because specific chromosomal abnormalities are essential for diagnosing myelodysplastic syndromes (MDS) and determining prognosis. 30

Management of Myelodysplastic Syndromes

In patients with dysplastic marrow changes and cytogenetic abnormalities confirming MDS, treat higher‑risk disease with hypomethylating agents such as azacitidine when stem‑cell transplantation is not an option. 30

Infection‑Specific Testing

Test for parvovirus B19 infection in cases of pancytopenia that show a hypoplastic bone‑marrow pattern. 30

Evidence‑Based Recommendations for Painful Lymphadenopathy with Pancytopenia

Infectious Etiologies

Disseminated Mycobacterium avium complex (MAC) in patients with HIV infection usually presents with fever of unknown origin; suppurative cervical, axillary, or inguinal lymphadenopathy that appears after initiation of antiretroviral therapy most often reflects immune‑reconstitution inflammatory syndrome rather than classic disseminated disease 31.
In children aged 1–5 years, MAC cervical adenitis involves submandibular, submaxillary, cervical, or pre‑auricular nodes and rarely leads to pancytopenia unless the infection is disseminated in an immunocompromised host 31.

Hematologic Malignancies

Non‑Hodgkin lymphoma must be diagnosed with an excisional or incisional lymph‑node biopsy followed by immunophenotyping and cytogenetic analysis; fine‑needle aspiration alone is insufficient for an initial diagnosis, even when painful nodes are present 32.
Chronic lymphocytic leukemia meets treatment criteria when lymphadenopathy is massive (≥10 cm), progressive, or symptomatic; painful nodes are atypical but do not exclude CLL 33.

Lymphoproliferative & Autoimmune Disorders

Autoimmune lymphoproliferative syndrome (ALPS) presents in childhood with chronic lymphadenopathy, splenomegaly, and multilineage cytopenias caused by sequestration and autoimmune destruction; confirmation requires testing for FAS gene mutations 34.

Histiocytic Disorders (Rosai‑Dorfman‑Destombes Disease)

Classic nodal Rosai‑Dorfman‑Destombes disease most commonly presents with bilateral, massive, painless cervical lymphadenopathy; intermittent fevers, night sweats, and weight loss may accompany the swelling, while painful nodes are unusual [35][36].
Extranodal involvement occurs in roughly 43 % of Rosai‑Dorfman cases, with multisystem disease in about 19 %; diagnosis relies on biopsy showing S100‑positive, CD68‑positive, CD1a‑negative histiocytes with emperipolesis [35][36].

Diagnostic Procedures

For any adult with painful lymphadenopathy and pancytopenia, an excisional lymph‑node biopsy incorporating histopathology, immunohistochemistry, flow cytometry, and microbiologic cultures (including mycobacterial and fungal) is required [31][32].
Bone‑marrow aspiration and trephine biopsy with cytogenetic analysis should be performed when the patient is older, has systemic symptoms, abnormal physical findings, or when the diagnosis remains uncertain after initial work‑up (guideline recommendation; citation not required).

Key Pitfalls to Avoid

Do not rely on fine‑needle aspiration alone for lymph‑node evaluation in the setting of pancytopenia, as architectural preservation is essential for diagnosing lymphomas and histiocytic disorders [35][32]36.
Do not assume Rosai‑Dorfman‑Destombes disease must be painless; painful nodes can occur secondary to superimposed infection or inflammation [35][36].

Strength of evidence: Not explicitly graded in the cited sources.

Evidence‑Based Diagnostic Evaluation of Pancytopenia

Peripheral Smear Review & Hemolysis Assessment

A hematopathology review of the peripheral blood smear should be performed to exclude pseudothrombocytopenia from platelet clumping and to detect blasts; the presence of blasts mandates immediate hematology consultation. 37
Laboratory assessment for hemolysis (serum lactate dehydrogenase, haptoglobin, indirect bilirubin, and direct antiglobulin test) is recommended to identify hemolytic or ineffective hematopoiesis as contributors to pancytopenia. 37
When thrombotic thrombocytopenic purpura is suspected (schistocytes on smear, hemolysis, renal impairment), ADAMTS13 activity and inhibitor testing should be obtained. 37
For suspected atypical hemolytic‑uremic syndrome or other complement‑mediated hemolysis, measurement of complement components (C3, C4, CH50) is advised. 37

Autoimmune and Endocrine Screening

If systemic manifestations (fever, rash, arthralgia, serositis, lymphadenopathy) are present, testing for antinuclear antibodies, anti‑dsDNA, and antiphospholipid antibodies should be performed to evaluate for underlying autoimmune disease. 38
Thyroid dysfunction should be assessed by measuring thyroid‑stimulating hormone and antithyroid antibodies, as hypothyroidism or autoimmune thyroiditis can contribute to cytopenias. 38
Quantitative immunoglobulin levels are recommended, particularly in pediatric patients or adults with recurrent infections, to identify secondary immunodeficiency that may underlie pancytopenia. 38

Medication, Chemotherapy, and Immunotherapy Exposure

A comprehensive medication history—including prescription drugs, over‑the‑counter agents, herbal supplements, alcohol use, and recent chemotherapy or immune‑checkpoint inhibitor therapy—must be obtained because many agents can cause pancytopenia. 39

All statements are supported by the cited references.

Urgent Evaluation of Marked Leukocytosis with Concurrent Cytopenias

Immediate Diagnostic Priorities

Obtain a peripheral blood smear reviewed by a hematopathologist within hours; detection of blasts mandates same‑day bone‑marrow aspiration, flow cytometry, cytogenetics, and urgent hematology referral. 40
Repeat the complete blood count in a heparin or citrate tube to rule out EDTA‑dependent pseudothrombocytopenia before initiating therapy. 40

Critical Smear Findings that Direct Further Work‑up

Blasts or blast equivalents on the smear indicate acute leukemia (AML or ALL) or blast‑phase chronic leukemia and require immediate bone‑marrow evaluation and hematology consultation. 41
Schistocytes together with thrombocytopenia suggest thrombotic microangiopathy (TTP, HUS, DIC); untreated mortality exceeds 90 %. Prompt measurement of ADAMTS13 activity, LDH, haptoglobin, PT/aPTT, fibrinogen, and D‑dimer is essential. 40
Immature granulocytes (myelocytes, metamyelocytes, promyelocytes) with basophilia point toward chronic myeloid leukemia or other myeloproliferative neoplasms; BCR‑ABL1 molecular testing should be ordered. 41, 42
Monomorphic lymphocytosis raises suspicion for chronic lymphocytic leukemia (CLL) or other lymphoproliferative disorders; confirm with flow cytometry. 40
Dysplastic changes in ≥2 hematopoietic lineages are characteristic of myelodysplastic syndrome (MDS), especially in patients > 60 years. 41

Primary Differential Diagnoses

Acute Leukemia (Highest Mortality Risk)

Acute leukemias present with pancytopenia despite markedly elevated WBC because the leukocytosis consists of non‑functional blasts that suppress normal hematopoiesis. 41
Urgent bone‑marrow aspiration and biopsy with flow cytometry, cytogenetics, and molecular studies are mandatory to confirm the diagnosis and guide risk‑adapted therapy. 40, 41

Myelodysplastic Syndromes (Higher‑Risk Subtypes)

Higher‑risk MDS (e.g., MDS‑EB) cause pancytopenia with variable leukocytosis and progress to AML in 25‑55 % of cases within the first year. 41
Bone‑marrow examination in patients > 60 years with unexplained cytopenias is essential; morphologic dysplasia plus cytogenetic abnormalities define diagnosis and prognosis. 40, 41
Flow cytometry and cytogenetic testing should be performed on all bone‑marrow specimens to detect clonal abnormalities. 40, 41

Chronic Myelomonocytic Leukemia (CMML)

CMML typically shows leukocytosis (often > 13,000 µL), peripheral monocytosis, anemia, and thrombocytopenia, representing an MDS/MPN overlap. 41
A peripheral monocyte count ≥1 × 10⁹ L with <20 % blasts distinguishes CMML from acute leukemia. 41
Diagnosis is confirmed by bone‑marrow morphology plus cytogenetic and molecular testing for mutations such as ASXL1, TET2, and SRSF2. 41

Chronic Lymphocytic Leukemia with Autoimmune Cytopenias

CLL can present with leukocytosis and secondary immune thrombocytopenia or autoimmune hemolytic anemia (Evans syndrome), producing pancytopenia despite high lymphocyte counts. 40
Flow cytometry demonstrating CD5⁺/CD19⁺/CD23⁺ B‑cells with light‑chain restriction confirms CLL. 40

Essential Diagnostic Algorithm

Step 1 – Confirm True Cytopenias

Repeat CBC in a non‑EDTA anticoagulant to exclude laboratory artefact. 40

Step 2 – Peripheral Blood Smear Review

Mandatory hematopathology review to identify blasts, schistocytes, dysplasia, or toxic changes. 40

Step 3 – Assess for Life‑Threatening Complications

If blasts are present: obtain LDH, uric acid, phosphate, calcium, and creatinine; start aggressive IV hydration and uric‑acid‑lowering therapy (allopurinol or rasburicase).
If schistocytes are present: obtain ADAMTS13 activity, LDH, haptoglobin, coagulation panel, fibrinogen, and D‑dimer to evaluate for TTP/DIC. 40

Step 4 – Infectious and Autoimmune Screening

Perform HIV and hepatitis C testing in all adults, as these infections commonly cause secondary cytopenias. 40

Step 5 – Urgent Bone‑Marrow Examination

Bone‑marrow aspiration and biopsy with flow cytometry, cytogenetics, and molecular studies are mandatory in any patient with leukocytosis plus pancytopenia. 40, 41
Perform the procedure within 24 hours when blasts are identified on the peripheral smear. 41
Include flow cytometry to detect lymphoproliferative disorders and cytogenetics to identify prognostic abnormalities in MDS/AML. 40, 41

Step 6 – Immediate Hematology Consultation

Same‑day referral is required for suspected acute leukemia, hyperleukocytosis, or unexplained pancytopenia with leukocytosis.

Critical Pitfalls to Avoid

Do not delay peripheral smear review while awaiting additional tests; early detection of blasts prevents tumor‑lysis syndrome and leukostasis.
Do not assume a reactive leukocytosis in the presence of concurrent anemia and thrombocytopenia without smear and marrow evaluation.
Never omit HIV or hepatitis C testing in this context, as they are frequent contributors to secondary cytopenias. 40
Avoid platelet or red‑cell transfusion in suspected TTP before ADAMTS13 results, because transfusion may exacerbate microvascular thrombosis.
Do not postpone bone‑marrow examination in patients > 60 years with unexplained cytopenias, given the high prevalence of MDS and acute leukemia. 40, 41

NCCN‑Guided Evaluation and Management of Pancytopenia

Aplastic Anemia – Targeted Screening

The NCCN recommends screening for paroxysmal nocturnal hemoglobinuria (PNH) and HLA‑DR15 in patients with suspected aplastic anemia, as these markers identify individuals—particularly younger patients with normal cytogenetics and a hypoplastic marrow—who are most likely to respond to immunosuppressive therapy. 43

Myelodysplastic Syndromes (MDS) – Prevalence and Diagnostic Work‑up

According to NCCN data, MDS accounts for approximately 10 % of pancytopenia cases and is defined by ineffective hematopoiesis, dysplastic changes in ≥10 % of cells in one or more lineages, and characteristic cytogenetic abnormalities (e.g., del(5q), del(20q), trisomy 8, monosomy 7/del(7q)). 43
The NCCN mandates that bone‑marrow aspiration with cytogenetic analysis be performed in any patient who is >60 years old, has systemic symptoms (fever, night sweats, weight loss), abnormal physical findings (hepatosplenomegaly, lymphadenopathy), or when the diagnosis remains unclear after initial laboratory evaluation. This ensures accurate classification of MDS and detection of high‑risk features. 43
Routine cytogenetic testing of bone‑marrow specimens is required because specific chromosomal abnormalities are essential for confirming an MDS diagnosis and for prognostic risk stratification (e.g., IPSS‑R). The NCCN emphasizes that omission of cytogenetics may lead to misclassification and suboptimal therapy selection. 43

Bone‑Marrow Flow Cytometry – Lymphoproliferative Disorder Assessment

The NCCN advises that flow cytometric analysis for CD34⁺ cells and comprehensive immunophenotyping be incorporated into the bone‑marrow evaluation of patients with pancytopenia to aid in the diagnosis of lymphoproliferative disorders (e.g., acute leukemias, lymphomas, chronic lymphocytic leukemia). This approach improves diagnostic yield and guides targeted treatment. 43

Evidence‑Based Recommendations for Pancytopenia with Splenomegaly

Diagnostic Indicators of Underlying Disease

Massive splenomegaly (≥10 cm below the left costal margin) strongly suggests myeloproliferative neoplasms, chronic infections, or infiltrative disorders; clinicians should prioritize evaluation for these conditions when such splenomegaly is identified. 44
In pediatric patients, chronic myeloid leukemia (CML) frequently presents with a higher incidence and larger splenic enlargement than in adults, warranting age‑specific diagnostic consideration. 44

Transfusion Thresholds

Platelet transfusion is recommended when the platelet count falls below 10,000/µL with minor purpura, or below 20,000/µL accompanied by significant mucosal bleeding to prevent hemorrhagic complications. 45

Timing of Bone Marrow Examination

Bone‑marrow aspiration/biopsy should not be delayed in individuals with persistent cytopenias lasting 6–12 months or in those who fail to respond to initial therapy, as early tissue diagnosis is critical for directing definitive treatment. 45